Everest Medicines Limited's latest marketcap:
As of 07/04/2025, Everest Medicines Limited's market capitalization has reached $2.78 B. According to our data, Everest Medicines Limited is the 5034th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 2.78 B |
| Revenue (ttm) | 95.76 M |
| Net Income (ttm) | -141,118,496.67 |
| Shares Out | 324.74 M |
| EPS (ttm) | -0.44 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 08/25/2025 |
Everest Medicines Limited's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 07/04/2025 | HK$2.78 B | 32.77% | 5034 |
| 12/31/2024 | HK$15.59 B | 132.87% | 5675 |
| 12/29/2023 | HK$6.7 B | 24.6% | 9561 |
| 12/30/2022 | HK$5.37 B | -47.96% | 10321 |
| 12/31/2021 | HK$10.33 B | -47.98% | 7894 |
| 12/31/2020 | HK$19.85 B | 4597 |
Company Profile
About Everest Medicines Limited
Everest Medicines Limited is a biopharmaceutical company focused on discovering, licensing, developing, and commercializing innovative therapies and vaccines for critical unmet medical needs in Greater China and the Asia Pacific region. Founded in 2017 and headquartered in Shanghai, China, the company is dedicated to advancing cutting-edge treatments across multiple therapeutic areas.
Key Pipeline Products
- Nefecon – An oral budesonide formulation for treating immunoglobulin nephropathy (IgAN).
- Xerava – A synthetic fluorocycline IV antibiotic targeting gram-positive, gram-negative, and anaerobic infections.
- Taniborbactam – A beta-lactamase inhibitor (BLI) in Phase 3 trials for serious bacterial infections.
- Etrasimod – An oral S1P receptor modulator in Phase 3 trials for moderate-to-severe ulcerative colitis.
- Zetomipzomib – An immunoproteasome inhibitor in Phase 2b trials for immune-mediated disorders like lupus nephritis.
- EVER001 – A BTK inhibitor in Phase 1b trials for renal diseases.
- mRNA Platform Vaccines – Therapeutic vaccines for cancer and autoimmune diseases.
- EVER206 – A polymyxin derivative in Phase 1 trials for MDR gram-negative infections with reduced toxicity.
Everest Medicines continues to expand its portfolio, addressing some of the most challenging medical conditions with innovative and targeted therapies.
Frequently Asked Questions
-
What is Everest Medicines Limited's (HKG-1952) current market cap?As of 07/04/2025, Everest Medicines Limited (including the parent company, if applicable) has an estimated market capitalization of $2.78 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Everest Medicines Limited (HKG-1952) rank globally by market cap?Everest Medicines Limited global market capitalization ranking is approximately 5034 as of 07/04/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.